Gregory Hirsch
Pulmonary Disease · Escondido, CANPI 1639287071
Payments from drug & device makers
Across 74 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$359
- GSK$321
- Intuitive Surgical$108
- Actelion Pharmaceuticals US, Inc.$84
- Genentech USA, Inc.$66
- Philips North America LLC$51
- plus $342 from 15 others
What the payments were for
- Food & beverage$1,31999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 20 | $359 |
| GSK | 20 | $321 |
| Intuitive Surgical | 1 | $108 |
| Actelion Pharmaceuticals US, Inc. | 5 | $84 |
| Genentech USA, Inc. | 3 | $66 |
| Philips North America LLC | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 5 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Grifols USA, LLC | 1 | $27 |
| Pfizer | 2 | $25 |
| Insmed, Inc. | 1 | $25 |
| Covis Pharma GmbH | 1 | $21 |
| Resmed Corp | 1 | $19 |
| Pulmonx Corporation | 1 | $19 |
| AbbVie | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Sanofi | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,331 in reported general payments places this provider in the 45th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $48,933 |
| Spiriva RespimatTiotropium Bromide | 25 | $13,798 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,593 |
| Roflumilast | 26 | $2,310 |
| CefoxitinCefoxitin Sodium | 14 | $867 |
| Amikacin Sulfate | 19 | $686 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $557 |
| Prednisone | 27 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $321 | $55,52776 claims |
| Boehringer IngelheimSpiriva Respimat | $359 | $13,79825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Escondido
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.